AbbVie Shares Rise 0.54% on Epcoritamab Trial Progress, Daily Volume Ranks 119th

On September 4, 2025, AbbVie (ABBV) closed with a 0.54% gain, trading at $213.51. The stock recorded a volume of 0.75 billion, ranking 119th in daily trading activity. The move followed updated data from AbbVie’s Phase 2 EPCORE NHL-6 trial evaluating epcoritamab, a bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

The trial demonstrated that outpatient administration of epcoritamab after the first full dose was feasible, with cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS) rates consistent with prior studies. Of 88 patients, 92% were monitored in outpatient settings. Adverse events were largely low-grade and resolved quickly, with no treatment discontinuations. Response rates were 64.3% overall and 47.6% complete responses in patients with one prior therapy. AbbVie highlighted the potential for expanded treatment access in community care settings.

Analysts noted that the trial’s positive safety profile and outpatient viability could strengthen epcoritamab’s market position in blood cancers. The drug, co-developed with Genmab, is already approved for R/R DLBCL but is being studied for earlier treatment lines. AbbVie emphasized its commitment to advancing oncology therapies, including partnerships and pipeline diversification.

Backtest results show ABBV’s trailing total return as of September 4, 2025, was +23.17% year-to-date, outperforming the S&P 500’s +10.55%. Over three years, it returned +74.96% versus the S&P 500’s +65.69%. The stock has maintained a positive trajectory despite sector volatility, with a focus on oncology and neuroscience driving growth.